Search results
Showing 676 to 690 of 1560 results for do not do recommendations
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.
Aortic valve reconstruction with processed bovine pericardium (HTG461)
Evidence-based recommendations on aortic valve reconstruction with processed bovine pericardium. This involves replacing a damaged aortic valve with a new valve made from chemically treated cow pericardium.
View recommendations for HTG461Show all sections
Transcutaneous electrical neuromuscular stimulation for urinary incontinence (HTG636)
Evidence-based recommendations on transcutaneous electrical neuromuscular stimulation for urinary incontinence in adults. This involves stimulating nerves and muscles in the pelvic floor to strengthen the muscles and reduce urine leaks.
View recommendations for HTG636Show all sections
Endoluminal gastroplication for gastro-oesophageal reflux disease (HTG661)
Evidence-based recommendations on endoluminal gastroplication for gastro-oesophageal reflux disease. This involves an endoscopic fastening device being inserted through the mouth and into the stomach, along with an endoscope for constant visualisation. The device is used to attach the fundus to the anterior and left lateral wall of the distal oesophagus slightly above the oesophagogastric junction.
View recommendations for HTG661Show all sections
Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.
Join NICE's people and communities network
Join NICE's people and communities network
Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.
Pegaspargase for treating acute lymphoblastic leukaemia (TA408)
Evidence-based recommendations on pegaspargase (Oncaspar) for treating acute lymphoblastic leukaemia.
Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.
Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
join a committee Your role as a NICE committee member What lay members do Register your organisation as a stakeholder People and...
join a committee Your role as a NICE committee member What lay members do Register your organisation as a stakeholder People and...
Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating non-small-cell lung cancer after chemotherapy in adults.
Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults.